Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 3Terminated 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Neoplasm Metastasis 40Lung Neoplasms 34Leukemia, Myeloid, Acute 34Breast Neoplasms 31Multiple Myeloma 25Carcinoma, Non-Small-Cell Lung 25Colorectal Neoplasms 23Prostatic Neoplasms 21Pancreatic Neoplasms 20Melanoma 17Carcinoma, Renal Cell 17Lymphoma 16Urinary Bladder Neoplasms 15Triple Negative Breast Neoplasms 15Ovarian Neoplasms 14Myelodysplastic Syndromes 14Burkitt Lymphoma 12Lymphoma, Large B-Cell, Diffuse 11Squamous Cell Carcinoma of Head and Neck 10Sarcoma 10Leukemia, Lymphocytic, Chronic, B-Cell 10Glioma 10Fallopian Tube Neoplasms 10Mouth Neoplasms 9Endometrial Neoplasms 9Carcinoma, Transitional Cell 9Carcinoma, Hepatocellular 9Carcinoma 9Oropharyngeal Neoplasms 8Laryngeal Neoplasms 8

Interventions

Tamoxifen 5Specimen Handling 4exemestane 2Letrozole 2Anastrozole 2fezolinetant 1elacestrant 1Testosterone 1Surgical Procedures, Operative 1Omacor 1Neoadjuvant Therapy 1FAPI-46 1Biopsy 14-hydroxy-N-desmethyltamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma, Intraductal, Noninfiltrating × Specimen Handling × 30 days × Clear all
NCT06195306 2026-05-20

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

National Cancer Institute (NCI)

Phase 2 Recruiting
66 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT05941520 2026-05-13

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
80 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06184750 2026-05-13

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
200 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06617455 2026-05-06

VEnT

University of Michigan Rogel Cancer Center

Phase 2 Terminated
9 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡